🕒 Last update: loading…19/11/2026

Stock Corvus Pharmaceuticals, Inc. CRVS

Corvus Pharmaceuticals, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 01/11/2026.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 48.23%

Price change 2019 → 2020: -34.56%

Price change 2020 → 2021: -32.30%

Price change 2021 → 2022: -64.73%

Price change 2022 → 2023: 107.06%

Price change 2023 → 2024: 203.98%

Price change 2024 → 2025: 43.93%

Price change 2025 → 2026: 25.05%

Price change 2026 (year to date): 31.54%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.02

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -15.89

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 40.56% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Corvus Pharmaceuticals, Inc.–0.01–🔒
Pharming Group N.V.40.00.42+50.2 %–
Vetoquinol S.A.16.60.03+4.2 %–
DocMorris AG–0.71+5.7 %–
Gerresheimer AG31.71.48+5.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Corvus Pharmaceuticals, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
34.52
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.23 x
low debt
Fiscal year20212022202320242025
Cash and investments69.5 m42.3 m27.1 m52.0 m56.8 m
Total Debt3.6 m2.6 m1.4 m1.1 m937,000
Net Debt-59.8 m-10.6 m-11.2 m-7.6 m-3.6 m
Equity97.2 m56.1 m38.7 m32.6 m61.2 m
Total assets109 m68.2 m45.6 m68.9 m71.1 m
Operating cash flow-36.7 m-27.0 m-23.9 m-25.4 m-32.8 m
Investments (capex)5,000269,00034,0000174,000
Free cash-flow-36.7 m-27.3 m-24.0 m-25.4 m-33.0 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-14.35 x
Price / book value4.71 x
Return on Equity (ROE)-35.0 %
Return on Invested Capital (ROIC)-32.4 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio13.38 x
Free cash-flow yield-5.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Corvus Pharmaceuticals, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
13 analysts

Breakdown of ratings

strong buy 0buy 12hold 1sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Corvus Pharmaceuticals, Inc.

Large funds tracked
20
hold the stock as of 2026Q2
Executives (insiders)
4 / 0
4 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street8.9 m134 m0.0 %+150.9 %2026Q2
BlackRock7.1 m107 m0.0 %+15.9 %2026Q2
T. Rowe Price3.8 m56.6 m0.0 %+29.9 %2026Q2
Wellington Management2.7 m40.8 m0.0 %+17.8 %2026Q2
Vanguard Group3.9 m29.8 m0.0 %+11.6 %2025Q4
Geode Capital Management1.9 m27.7 m0.0 %+8.2 %2026Q2
Goldman Sachs1.6 m23.6 m0.0 %+2.3 %2026Q2
Morgan Stanley1.3 m20.1 m0.0 %-46.2 %2026Q2

Latest insider transactions

DatePersonSideAmount
13/11/2026Arcara Jeffreypurchase5,216 USD
13/11/2026Arcara Jeffreypurchase5,354 USD
12/11/2026Arcara Jeffreypurchase5,524 USD
11/11/2026Arcara Jeffreypurchase34,381 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 18/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 23/03/2016
ISIN code
US2210151005
Workforce
31
full-time employees
Chief executive
Richard A. Miller

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Corvus Pharmaceuticals, Inc.

What is the Corvus Pharmaceuticals, Inc. share price?

Latest recorded price: 10.64 USD on 13/11/2026, for a market cap of 898 m USD.

What do analysts say about Corvus Pharmaceuticals, Inc.?

Out of 13 analysts: 12 buy or strong buy, 1 hold, 0 sell or strong sell.

Is Corvus Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US2210151005).

How many employees does Corvus Pharmaceuticals, Inc. have?

31 full-time employees according to the latest published profile.

Who runs Corvus Pharmaceuticals, Inc.?

Richard A. Miller is the company's chief executive.

Which large funds own Corvus Pharmaceuticals, Inc.?

As of 2026Q2, among the large funds tracked: State Street, BlackRock, T. Rowe Price, Wellington Management, Vanguard Group.

07

Similar stocks